Global Viral Vector Manufacturing Market Anticipated to Undergo Strong Growth Through 2030

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Growth Potential of the Viral Vector Production (Research-Use) Market in the Next Decade?
The viral vector manufacturing market size has grown rapidly in recent years. It will grow from $8.26 billion in 2025 to $9.9 billion in 2026 at a compound annual growth rate (CAGR) of 19.9%. The growth in the historic period can be attributed to limited manufacturing capacity, high production cost, reliance on traditional gene delivery methods, regulatory barriers, fragmented supply chains.

The viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $21.31 billion in 2030 at a compound annual growth rate (CAGR) of 21.1%. The growth in the forecast period can be attributed to growing demand for gene and cell therapies, advancements in viral vector technology, increased R&D investments, expansion of contract manufacturing organizations, rising adoption of personalized medicine. Major trends in the forecast period include gene therapy innovation, viral vector safety optimization, scalable manufacturing processes, regulatory compliance enhancement, advanced upstream and downstream processing.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

What Are the Key Drivers of the Viral Vector Manufacturing Market?
The increase in the prevalence of cancer and infectious diseases is expected to propel the growth of the viral vector manufacturing market going forward. An infectious disease refers to a condition brought on by a virus or its toxic byproduct and spread to a susceptible host via contact with an infected person, animal, or item. Cancer refers to a broad range of illnesses that can develop in any organ or tissue of the body when aberrant cells grow out of control, cross their usual boundaries to invade neighboring organs, and spread to other organs. Tumor antigens, or proteins on tumor cells, are produced via viral vectors to elicit the body's anticancer immune response. In pre-clinical and clinical trials, viral vectors have served as vaccines against various infectious illnesses. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in Australia the number of cancer cases diagnosed increased from 160,570 in 2022 to 164,694 in 2023, reflecting a notable rise over the year. This upward trend highlights the growing prevalence of cancer within the country. Furthermore, in August 2024, according to the data published by the UK Health Security Agency, a UK-based executive agency, in England, the UK Health Security Agency (UKHSA) reported 368 measles cases in 2023, marking a nearly sevenfold increase from the 53 cases reported in 2022, with the West Midlands and London accounting for 44% and 33% of the cases, respectively. Therefore, the increase in the prevalence of cancer and infectious diseases is driving the growth of the viral vector manufacturing market.

What Are the Main Segments of the Viral Vector Manufacturing Market?
The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types
2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases
3) By Workflow: Upstream Processing, Downstream Processing
4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research
5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Other End Users

Subsegments:
1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26
2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others
3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others
4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others
5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

Which Emerging Trends Are Driving the Viral Vector Manufacturing Market?
Major companies operating in the viral vector manufacturing market are focusing on developing advanced products, such as viral vector platforms specifically designed for viral vector production and manufacturing. Viral vector platforms are comprehensive systems tailored to efficiently produce and process viral vectors for applications such as gene therapy and vaccine development. For instance, in May 2023, AGC Biologics, a US-based global biopharmaceutical contract development and manufacturing organization (CDMO), launched the BravoAAV and ProntoLVV platforms, designed to offer flexible and accelerated vector development and manufacturing for cell and gene therapy programs. These platforms, designed for flexible and accelerated vector development and manufacturing in cell and gene therapy programs, offer GMP product delivery in nine months, supported by a global regulatory and supply network and in-house plasmid DNA services. With custom processes, templated material approaches, and prequalified analytical methods, these platforms are significant contributors to the viral vector manufacturing market's projected growth, reaching $5.5 billion by 2035, by meeting the increasing demand for efficient development and delivery of life-changing gene therapies and vaccines.

Which Major Companies Are Operating in the Viral Vector Manufacturing Market?
Major companies operating in the viral vector manufacturing market are Sanofi S.A., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV

Get the full viral vector manufacturing market report here:
https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Which region represents the fastest-growing market for the Viral Vector Manufacturing Market?
North America was the largest region in the viral vector manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn